1. Home
  2. GRC vs URGN Comparison

GRC vs URGN Comparison

Compare GRC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRC
  • URGN
  • Stock Information
  • Founded
  • GRC 1933
  • URGN 2004
  • Country
  • GRC United States
  • URGN United States
  • Employees
  • GRC N/A
  • URGN N/A
  • Industry
  • GRC Fluid Controls
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRC Industrials
  • URGN Health Care
  • Exchange
  • GRC Nasdaq
  • URGN Nasdaq
  • Market Cap
  • GRC 1.1B
  • URGN 904.0M
  • IPO Year
  • GRC N/A
  • URGN 2017
  • Fundamental
  • Price
  • GRC $42.91
  • URGN $18.79
  • Analyst Decision
  • GRC
  • URGN Strong Buy
  • Analyst Count
  • GRC 0
  • URGN 8
  • Target Price
  • GRC N/A
  • URGN $28.50
  • AVG Volume (30 Days)
  • GRC 60.5K
  • URGN 1.1M
  • Earning Date
  • GRC 10-24-2025
  • URGN 11-05-2025
  • Dividend Yield
  • GRC 1.72%
  • URGN N/A
  • EPS Growth
  • GRC 51.35
  • URGN N/A
  • EPS
  • GRC 1.97
  • URGN N/A
  • Revenue
  • GRC $673,880,000.00
  • URGN $94,238,000.00
  • Revenue This Year
  • GRC $4.94
  • URGN $35.60
  • Revenue Next Year
  • GRC $4.47
  • URGN $129.54
  • P/E Ratio
  • GRC $21.77
  • URGN N/A
  • Revenue Growth
  • GRC 2.60
  • URGN 10.85
  • 52 Week Low
  • GRC $30.87
  • URGN $3.42
  • 52 Week High
  • GRC $43.98
  • URGN $21.71
  • Technical
  • Relative Strength Index (RSI)
  • GRC 54.85
  • URGN 48.50
  • Support Level
  • GRC $41.98
  • URGN $18.45
  • Resistance Level
  • GRC $43.98
  • URGN $21.71
  • Average True Range (ATR)
  • GRC 0.92
  • URGN 1.18
  • MACD
  • GRC -0.07
  • URGN -0.18
  • Stochastic Oscillator
  • GRC 49.53
  • URGN 17.51

About GRC Gorman-Rupp Company (The)

Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: